M ultiple sclerosis (MS)
3 is an inflammatory and demyelinating disease of the CNS with major socioeconomic impact (1) . Besides environmental stimuli, genetic factors determine disease outbreak. There is an increased risk for patients being HLA-DRB1*1501, DRB5*0101, and DQB1*0602, which are contained in the Dw2 haplotype to develop MS, and HLA-DRB1*1501 is associated with an earlier age of disease manifestation (2) . Myelin-specific autoreactive T cells pass the blood brain barrier and initiate an autoimmune attack against myelin sheaths in the CNS (3) . Depending on the degree of the myelin sheath-specific autoimmune attack, axons can also be harmed, leading to irreversible axonal loss and long-term global brain atrophy (4) . Several myelin proteins are thought to be targets of tissue damage in MS (5) . Much attention has been given to myelin-basic protein (MBP) and proteolipid protein. More recently, myelin oligodendrocyte glycoprotein (MOG) has gained considerable attention with regard to the autoimmune attack in MS (6) . This is due to the high histopathological similarity between MOG-induced animal models and biopsies from MS patients, both showing large demyelinating lesions and axonal loss (7, 8) . MOG only composes ϳ0.01% of the protein content of the myelin sheath and is exposed on its outer surface (6) . It has an extracellular part including aa 1-122 with an Ig-like domain, a transmembrane part, and an intracellular part comprising aa 123-218 ( Fig. 7 ; Refs. 9 -11) . Up to now, T cell responses against the extracellular part of MOG have been mainly looked at. Using the ELISPOT methodology, Wallström et al. (12) demonstrated increased IFN-␥-secreting cells in HLA-DR2 (15) positive MS patients compared with controls toward several MOG peptides among which MOG 63-87 was immunodominant. Others investigated T cell responses to MOG of non-HLA-stratified MS patients and controls indicating increased T cell reactivity to MOG in MS patients (13) (14) (15) . Also, MOG-specific B cell responses are up-regulated in MS, and MOGspecific Abs contribute to lesion formation (16 -17) . Because MOG can be considered an important autoantigen in MS and a potential target for therapy, we investigated T cell responses by ELISPOT assay for IFN-␥-secreting cells to peptides of the complete human MOG 1-218 sequence. We used the ELISPOT assay to detect IFN-␥-secreting cells, because this is more sensitive than proliferation as assessed by [ 3 H]TdR-uptake, and adds a functional outread. We demonstrate a previously unknown dominant T cell epitope that is recognized in context of HLA-DR molecules by CD4 ϩ T cells within the transmembrane and intracellular sequence 146 -154 of MOG in MS patients and controls.
Materials and Methods

Subjects
MS patients and controls were stratified for HLA-DRB1*1501. This resulted in four groups with 11 MS patients and 10 controls being HLA-DRB1*1501 positive, and 7 MS patients and 10 controls being HLA-DRB1*1501 negative. A total of 13 patients had a relapsing-remitting MS disease course with an average disease duration at a sample collection of 1 year and 6 mo (mean expanded disability status scale (EDSS) 2.0). Four patients had a secondary progressive disease course at sample collection with an average disease duration of 8 years (mean EDSS 5.0), and one patient had a primary progressive disease course with a duration of 7 years at sample collection (EDSS 6.5). Sixteen of 18 patients had not been treated at all or had not received any immunosuppressive or immunomodulatory treatment for at least 1 year before sample collection. Two of 18 patients had not received immunosuppressive or immunomodulatory treatment for 1 mo before sample collection. All patients were admitted to Department of Neurology of the University of Tubingen (Tubingen, Germany) due to acute relapse (relapsing remitting disease course) or fast worsening of neurological deficits (primary or secondary progressive disease course). The mean age of MS patients was 34 Ϯ 9 years and of controls 38 Ϯ 11 years, with a male to female ratio of 50:50% in MS patients and 55:45% in controls. The age distribution and female:male ratio was equal in the HLA-DRB1*1501 positive and negative groups. The studies had been approved by the ethical review board of the University of Tübingen.
HLA-typing
Genomic DNA for HLA-genotyping was prepared by the QIAampBlood kit (Qiagen, Hilden, Germany). Low resolution pregenotyping was performed for the 116 major HLA-DRB1, -DRB3, -DRB4, -DRB5, and 29 HLA-DQB alleles, and HLA-DR or HLA-DQ subtyping was done specifically for the pretyped HLA-DRB1/DQB1 alleles by group-specific amplification and subsequent direct sequencing in patients and controls.
Cloning and bacterial expression of recombinant human (rh)MOG 1-125
The cDNA of rhMOG was obtained by reverse transcription of total RNA from a human glioma cell line. RNA was prepared with TRIzol reagent (Life Technologies, Gaithersburg, MD) and first strand cDNA was synthesized using Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI) and the gene-specific primer R785. The amplified PCR product that contains the whole coding sequence of MOG mRNA was separated by agarose gel electrophoresis and purified with a QIAEXII-kit (Qiagen). The cDNA fragment was cloned into Bluescript II KS ϩ vector (Stratagene, La Jolla, CA). The DNA sequence encoding the extracellular domain of the mature protein (including four N-terminal amino acids of the transmembrane domain) was PCR-amplified and subcloned in pQ60 (Qiagen). The Escherichia coli-expressed His-tagged fusion protein (rhMOG 1-125) was purified under denaturing conditions by metal chelate affinity chromatography on Ni-NTA agarose columns (Qiagen) according to the manufacturer's guidelines.
Synthesis and analysis of peptides
The 16 aa-long peptides (Table I ) and the N-acetylated C-amidated 9 aalong peptides (Table II) were prepared by solid phase peptide synthesis using F-moc/tBu chemistry. The peptides were purified by preparative HPLC (Abimed, Langenfeld, Germany). The identity of the purified peptides was confirmed by electrospray mass spectrometry. The purity of peptides was Ͼ95% as determined by analytical HPLC (Abimed). MBP 85-99 (ENPVVHFFKNIVTPR) and influenza A peptide (YRNLVWFIKKN-TRYP) (18) were synthesized and purified in the same way. The peptides were used at a concentration of 10 g/ml in all experiments. This concentration had given the highest number of spots in ELISPOT analyses in pilot experiments (data not shown).
Mitogen
PHA was purchased from Sigma-Aldrich (Deisenhofen, Germany) and used in a concentration of 3 g/ml in all experiments. This concentration had given optimal results in preceding experiments.
Purification of PBMC
PBMCs were isolated from heparinized blood samples on Lymphoprep density gradients (Nyegaard, Oslo, Norway; 200 ϫ g, 25 min, room temperature). Cells were frozen at a density of 5 ϫ 10 6 cells/ml in freezing medium containing 40% FCS Gold (PAA, Linz, Austria), 10% DMSO (Serva, München, Germany), and 50% complete medium (CM) consisting of RPMI 1640 (Life Technology, Eggenstein, Germany) supplemented with 2 mM glutamine (Life Technology), 100 U/ml of penicillin, 100 g/ml of streptomycin (Biochrom, Berlin, Germany), and 3% heat-inactivated human AB serum in liquid nitrogen. The cells were recovered by thawing in a 37°C water bath until the cells reached the melting point and then by adding 1 ml CM per 5 ϫ 10 6 cells three times every 5 min at room temperature. Thereafter, the cells were washed three times in CM and resuspended at a density of 10 6 /ml in CM. The viability was 90 -95%.
ELISPOT analysis for IFN-␥-secreting cells and restriction analysis
Ninety six-well nitrocellulose plates (Millipore, Molsheim, France) were coated with 10 g/ml capture mAb 1-D1K (Mabtech, Stockholm, Sweden) overnight at 4°C. After washing, the membrane was blocked with culture medium containing 10% FCS (FCS Gold, PAA) for 1 h. A total of 2 ϫ 10 5
PBMCs/well were cultured for 40 h in 37°C, 5% CO 2 . For each Ag or mitogen, triplicates were used. Each plate contained a positive and negative control. All peptides and mitogens were tested for one patient or control at the same time point with exactly the same procedures. After 40 h, the cells were discarded and the membranes were thoroughly washed by immersing the plates six times in PBS. To visualize areas of the membrane that had bound secreted IFN-␥, biotinylated detector mAb 7-6B-1 (1 g/ml, Mabtech) was added for 3 h and staining performed with avidin-biotin peroxidase complex (Vectastatin Elite ABC kit; Vector Laboratories, Burlingame, CA) and chromogen solution containing carbazole (Sigma-Aldrich). Areas of the membrane where a specific color reaction had occurred appeared as dark brown-red spots and were both counted by an automated ELISPOT counter (Autoimmun-Diagnostika, Albstadt, Germany) and manually cross-checked. The average number of spots in triplicates secreted after exposure with Ag or mitogen were expressed as numbers of IFN-␥-secreting cells per 2 ϫ 10 5 cells added initially to the wells. For the restriction analysis, the HLA typing Abs Genox with the specificity anti-HLA-DQ and/or Tü 36 with the specificity anti-HLA-DR were added at a concentration of 10 g/ml to the cultures. These concentrations of Abs had given optimal results in pilot experiments (data not shown).
Enrichment of IFN-␥-secreting cells and FACS analyses
Enrichment of cells secreting IFN-␥ after contact with Ag was performed with magnetic cell separation as described by the manufacturer (IFN-␥ secretion assay; Miltenyi Biotec, Bergisch Gladbach, Germany). PBMC from MS patients and controls were incubated with no Ag, MOG 146 -154 (10 g/ml), or as a positive control staphylococcal enterotoxin B (SigmaAldrich, 10 g/ml) for 12 h at a concentration of 5 ϫ 10 6 cells/ml at 37°C, 5% CO 2 . Thereafter, cells were exposed to a bivalent Ab to IFN-␥ and leukocyte surface Ag (Miltenyi Biotec) at 4°C resulting in an activity matrix for IFN-␥ on the cell surface. Subsequently, cells were reinduced to secrete IFN-␥ at 37°C, 5% CO 2 . Secreted IFN-␥ is captured by the activity matrix on the cell surface. Next, cells were incubated with a PE-labeled Ab to IFN-␥ (Miltenyi Biotec). Finally, cells with bound IFN-␥ on their cell surface were separated with a PE-specific microbead (Miltenyi Biotec) in a magnetic field. Cells were analyzed for expression of IFN-␥ (mouse PE-labeled anti-human IFN-␥; Miltenyi Biotec) and CD4 (mouse FITClabeled anti-human CD4; BD Biosciences, Lincoln Park, NJ) and/or CD8 (mouse FITC-labeled anti-human CD8) expression following standard procedures by FACS (BD Biosciences).
Peptide binding assay
Relative affinities of MOG peptides for purified HLA-DRB1*1501 and HLA-DRB1*0401 molecules were measured by an inhibition ELISA based on a dissociation-enhanced lanthanide fluoroimmunoassay (Wallac, Turku, Finland). In the inhibition ELISA, HLA-DR (50 nM) molecules were incubated with fixed amounts of respective tracer peptides (10 -50 nM) in the presence of a range of dilutions of the unlabeled MOG-peptides (10-fold dilutions between 1 nM and 100 M). The binding buffer consisted of a carbonate buffer titrated to pH 5 containing 2 mM EDTA, 0.01% azide, 0.1 mM PMSF, and 0.1% Nonidet P-40 (Boehringer Mannheim, Indianapolis, IN). After an incubation of 48 h at 37°C, the peptide-MHC complexes were transferred to Ab-coated (L243) ELISA plates (FluoroNunc; Nunc, Roskilde, Denmark) to remove the excess of nonbound peptides. Europiumlabeled streptavidin (Wallac) was added to the plates and incubated for 1 h at room temperature. Finally, the plates were treated with an enhancement solution (Wallac), which releases chelated europium from streptavidin and forms a highly fluorescent solution that can be measured by using a dissociation-enhanced lanthanide fluoroimmunoassay fluorometer (Wallac). The peptide concentration yielding 50% inhibition of binding of the tracer peptide (IC 50 ) was determined by plotting the percentage of inhibition vs the concentration of added MOG peptide. Peptides were tested in two to three independent experiments.
Statistical analysis
Repeated measures ANOVA on signed ranks were used with the Dunnett's test (Sigma Stat; Jandel Scientific, San Rafael, CA). The Friedman repeated measures analysis of variance on ranks (repeated measures ANOVA on signed ranks) is a parametric test that compares effects of a series of different experimental treatments on a single group. Each subject's responses are ranked from smallest to largest without regard to other subjects, then the rank sums for the subjects are compared. Dunnett's test is the analog of the Student-Newman-Keuls test for the case of multiple comparisons against a single control group. It is conducted similarly to the Bonferroni t test, but with a more sophisticated mathematical model of the way the error accumulates to derive the associated table of critical values for hypothesis testing. This test is less conservative than the Bonferroni test, and is only available for multiple comparisons vs a control. This analysis was performed independently for each of the four groups (DRB1*1501 positive MS patients, DRB1*1501 positive controls, DRB1*1501 negative MS patients, DRB1*1501 negative controls). As controls, the individual background reactivities were used (T cell responses without Ag).
Results
T cell repertoire analysis to the extracellular part of MOG
We stimulated PBMCs from MS patients and controls with 52 overlapping peptides covering the complete human MOG sequence (Table I) or with the extracellular rhMOG 1-125 (mature peptide, aa 1-125) and enumerated IFN-␥-secreting cells with the ELISPOT assay ( Figs. 1 and 2 ). The T cell responses as assessed by IFN-␥ secretion toward peptides of the extracellular part of MOG were weak and heterogeneous. HLA-DRB1*1501 positive controls showed responses to peptide MOG 81-96 ( p Ͻ 0.05) (Fig. 2) , while MS patients and HLA-DRB1*1501 negative controls reacted weakly (NS). Some controls reacted with MOG 73-88 (NS), but not MS patients (NS). Only a few individuals had IFN-␥-producing cells that reacted with rhMOG 1-125 (NS). Background values for nonstimulated cultures did not differ significantly between MS patients and controls (NS) (data not shown).
T cell repertoire analysis to the transmembrane and intracellular part of MOG
Compared with the extracellular part of MOG, more reactive T cells were present to the transmembrane and intracellular part of MOG in MS patients and controls ( (Fig. 1 , individual quantitative data shown for one HLA-DRB1*1501 positive patient). All investigated subjects showed T cell responses to PHA of at least 1000 spots per 2 ϫ 10 5 PBMC (data not shown).
MOG 146 -154 is the dominant T cell determinant
We analyzed the region within MOG 141-160 more in detail with overlapping nine amino acid-long N-acetylated C-amidated peptides (Table II, Fig. 3 To exclude an influence of disulfide bonds or posttranslational modifications of cysteine (C), we investigated the T cell responses with a modified peptide containing valine (V) instead of cysteine (C) in position 148 (Ac-LVFLCLQYR-NH 2 3 Ac-LVFLVLQYR-NH 2 ). There was no decreased reactivity to this peptide in MS patients or controls (data not shown).
T cell reactivity to influenza A peptide
To exclude a generally decreased immune reactivity in MS patients, we measured T cell reactivities to an influenza A peptide (YRNLVWFIKKNTRYP) (18), with ELISPOT assay for IFN-␥ secreting cells. MS patients and controls reacted similarly to this peptide arguing against a generally compromised immune status in MS patients (NS) (data not shown).
Phenotypic analysis of MOG 146 -154 reactive cells
To determine the phenotype of IFN-␥-secreting MOG 146 -154 reactive T cells, we performed enrichment of these cells and subsequent FACS analysis for expression of CD4 or CD8 and IFN-␥. MOG 146 -154-specific T cells expressing IFN-␥ were enriched by the IFN-␥ enrichment assay in three MS patients (two HLA-DRB1*1501 positive, one HLA-DRB1*1501 negative) and one control (HLA-DRB1*1501 positive). The MOG 146 -154-reactive IFN-␥-secreting T cells were of the CD4 phenotype (Fig. 4) .
Restriction analysis of MOG 146 -154-reactive cells
The restriction pattern of MOG 146 -154 reactive T cells was assessed in a HLA-DRB1*1501 positive and a negative MS patient and a HLA-DRB1*1501 positive control. The T cell response was HLA-DR restricted in the investigated HLA-DRB1*0701 DRB1*15011 DQB1*02ϫ DQB1*0602 MS patient and in the HLA-DRB1*1103 DRB1*15011 DQB1*0301 DQB1*0602 control as well as in a HLA-DRB1*0701 DRB1*0407 DQB1*02ϫ DQB1*0301 MS patient, because only anti-HLA-DR Abs (Tü 36) resulted in decreased T cell responses as compared with addition of anti-HLA-DQ Abs (Genox) (Fig. 5) .
Binding of MOG 141-160-derived peptides to purified HLA-DRB1*1501 and HLA-DRB1*0401 molecules
We assessed binding affinities of MOG 141-156, MOG 145-160, the complete set of single stepped MOG peptides covering the region MOG 141-160, MBP 85-99, and influenza A peptide to purified HLA-DRB1*1501 and HLA-DRB1*0401 molecules. MOG 141-156 and MOG 145-160, as well as influenza A peptide and MBP 85-99 bound to both alleles. The strength of the binding for these peptides differed in both alleles with HLA-DRB1*1501 binding all four peptides with a higher affinity as indicated by a lower IC 50 and a higher 1/IC 50 (Fig. 6 ). Large differences emerged in the binding patterns of the shorter N-acetylated C-amidated nine amino acid-long stepped MOG peptides. HLA-DRB1*1501 molecules bound all these peptides with low to high affinity, depending on the peptide sequence (Fig. 6 ). In contrast, HLA-DRB1*0401 only bound peptides MOG 144 -152, MOG 145-153, and MOG 146 -154 with a weak affinity (Fig. 6) 
Discussion
This study demonstrates for the first time that 1) there is a dominant MOG epitope recognized by CD4 ϩ T cells within the intracellular part of MOG comprising aa 146 -154 in MS patients and controls; 2) MS patients show a more focused T cell reactivity pattern toward MOG compared with controls; 3) the dominant MOG T cell epitope is promiscuously recognized in context of several MHC class II molecules; and 4) the intracellular part of MOG is much more immunogenic compared with the extracellular part.
In animal models with marmosets, rats, and mice, the extracellular part of MOG leads to a very MS-like disease (7, 24 -26) (Fig.  7) . In addition, Amor et al. (25) investigated the encephalitogenic potential of peptides derived from the transmembrane and intracellular part of MOG in Biozzi AB/H and SJL mice. Our study is the first systematic study investigating T cell responses in MS patients and controls to peptides of the complete MOG sequence. Interestingly, besides the T cell responses to MOG 81-96, only minor T cell responses to the extracellular part of MOG were detectable. In contrast, several stretches of the transmembrane/intracellular domain of MOG proved to be highly immunogenic. We defined an immunodominant T cell epitope encompassing MOG 146 -154 with N-acetylated and C-amidated nine amino acid-long peptides that can bind to MHC class II molecules. There was no major HLA-guided influence on the selection of T cells arguing for promiscuous presentation of this MOG peptide on MHC class II molecules. In the tested MS patients and controls, the MOG 146 -154-specific T cell response was HLA-DR restricted. We assessed in vitro binding affinities of MOG peptides spanning MOG sequence 141-160 to two purified HLA-DR molecules. Both HLA-DRB1*1501 as well as HLA-DRB1*0401 molecules bound MOG 146 -154 to a varying degree allowing presentation of this peptide to T cells. Interestingly, HLA-DRB1*1501 molecules bound more of the nine amino acid-long MOG peptides within the sequence MOG 142-160 compared with HLA-DRB1*0401 molecules. Both alleles bound MOG 146 -154 slightly better than MBP 85-99 that is the major HLA-DRB1*1501-restricted MBP stretch in MS patients (19 -23) .
Our results of promiscuous recognition of MOG 146 -154 by T cells in context of several MHC class II molecules are partly in line with T cell reactivity to MBP in MS patients and controls. The immunodominant MBP 84 -102 and MBP 87-106 peptides and their core sequence MBP 89 -99 are recognized in the context of several MHC molecules in man as well as in mice and rats (19 -23, 27) . This MBP stretch induces experimental autoimmune encephalomyelitis (EAE) in HLA-DR2 transgenic mice (28) . In future studies, our laboratories will assess the immunogenic and encephalitogenic potential of intracellular MOG determinants in animal models.
Epitope mapping studies in humans with regard to myelin-Ags have shown conflicting results as far as reactivity patterns of T cell responses in diseased individuals compared with controls are concerned. Some studies have shown that there is an increased frequency of autoreactive T cells from blood in diseased individuals and that T cell reactivity is increased in MS patients, while others recorded negative findings in regard with disease-associated differences in blood (12, 23, 29) . Especially IFN-␥-secreting cells have been shown to be elevated in diseased individuals in blood and cerebrospinal fluid (30) . Our study is partly contradictory to these observations because controls showed even more T cell reactivities in blood ex vivo compared with MS patients. Importantly, we did not find a generally compromised immune status in regard to PBMC reactivity in MS patients that would have explained this finding, because T cells from blood reacted similar to an influenza A peptide in MS patients and controls (18) .
We did not observe the same reactivity profile to the extracellular part of MOG as Wallström et al. (12) had demonstrated with MOG 63-87 being immunodominant. Reasons might lie in differences in the genetic background of the patients and the preceding Ag exposure with effects on the T cell repertoire in the Swedish compared with the German MS population (31) . Additionally, compared with the explicit strength of the T cell responses to MOG 81-96 in some MS patients and controls and intracellular MOG in our study, in this preceding study the T cell responses as assessed by IFN-␥ ELISPOT were very weak with 3-4 spots in mean per 1 ϫ 10 5 PBMC to the immunodominant MOG 63-87. In this study, beside MOG 63-87 also MOG 76 -100 was slightly more recognized by MS patients compared with controls (1-2 spots per 1 ϫ 10 5 PBMC) (12 (25) . The data underscores the need to evaluate encephalitogenic MOG responses in humanized animal models additionally to inbred mouse and rat strains (34) .
In MOG-induced EAE in LEW.1N rats, we have recently shown that MHC class II-regulated CNS autoaggression and T cell responses in peripheral lymphoid tissues are dissociated (26) . The major encephalitogenic MOG 91-108 peptide in LEW.1N rats did not induce a detectable proliferative response and T1 or T2 T cell response in lymph nodes or spleen ex vivo after active immunization with MOG 91-108 or MOG 1-125. Instead, in the target tissue, the CNS, strong cellular, and cytokine responses were present after immunization with this peptide (26) . In contrast, there were several determinants within MOG 1-125 that did raise strong T cell responses in peripheral lymphoid tissue, but did not induce disease (26) . These data point to the need to investigate diseaseassociated cellular responses within the target organ (35) . Unfortunately, investigations of the intra-CNS immune response in humans are difficult to perform because the availability of cerebrospinal fluid is limited and there are a number of ethical problems.
There was a focusing of the T cell reactivity patterns toward MOG 141-160 in MS patients. The decreased number of T cell determinants in MS patients could reflect alteration of the T cell repertoire by preceding Ag exposure after damage of the blood brain barrier leading to a state of peripheral T cell tolerance to certain MOG determinants (36) . Moreover, migration of encephalitogenic T cells in MS patients to the target organ and reduction of the size of the T cell pool in blood reactive with MOG cannot be excluded at present (3, 37) . Such a scenario would argue for a pathogenic role of the T cell reactivities that are absent or reduced in the blood of MS patients compared with controls in the disease process and again forces investigations at the target organ site. Alternatively, other functional differences might exist between the MOG reactive T cells secreting IFN-␥ of MS patients and controls. Moreover, regulatory mechanisms could be up-regulated in MS patients after establishment of disease reducing the reactivity profile of T cells to MOG determinants in blood and lymphoid organs like up-regulation of TGF-␤ (38) or increased NK cell reactivity (39) .
Our data indicate that during thymic selection, MOG 146 -154 cross-reactive T cells must be positively selected on several HLA class II molecules and not deleted. In EAE, it has been recently shown that intrathymic expression of myelin components can lead to tolerance (40) . Compared with other proteins of the myelin sheath, the expression of MOG is low because it comprises only 0.01% of the protein content of the myelin sheath (6) . To date, no expression of human MOG on non-CNS tissue including the thymus has been reported, but it is not excluded that MOG is expressed at a very low level in the thymus. Potentially, this absent or low level expression would allow escape of MOG-specific T cells from negative selection in the thymus (40) . The extracellular part of MOG shows homology to butyrophilins and B7 family members that are expressed in the thymus (41) . In rats, butyrophilins have been shown to be cross-reactive with the extracellular part of MOG (42) . In contrast, structural similarities between selfproteins and the transmembrane or intracellular domain of MOG have not been described to the same degree as to the extracellular part of MOG. As a consequence, central tolerance mechanisms might result in more effective negative selection of T cells reactive to the extracellular part of MOG compared with the intracellular part. This would explain the high number of IFN-␥-secreting cells against the intracellular part of MOG present in the periphery.
